《外圍股市》道指期貨回吐20點 納指期貨續升8點跑贏
輝瑞與BioNTech新冠疫苗正式獲準於美國全面使用後,投資者風險胃納持續升溫,納指及標普屢創紀錄高。亞太區股市今天高位普遍遇壓,日經先續升逾160點至27,897無以爲繼,收市倒跌7點;港股受累於匯控(00005.HK)/建行(00939.HK)/中國平安(02318.HK)跌近1%-2%、安踏(02020.HK)挫7%,以及阿裏巴巴(09988.HK)倒跌逾1.5%,由今早曾升254點或1%至25,982(受制20天線),掉頭低見25,548,現報25,587,倒跌140點或0.55%。不過,臺股及菲股高收分別續升1.4%及2.2%。滬指及屢破頂新西蘭股市續升0.6%及0.8%,餘下升幅均少於0.5%。
美股連日上升後,期貨好淡爭持,持續跑輸道指期貨報35,294,回吐20點;屢破頂標普五百期貨報4,481,微吐1點;屢破頂納指一百期貨續跑贏,報15,363,續升8點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.